Runway Growth Finance (RWAY) Q1 2026 earnings summary

Executive summary

• Completed the acquisition of SWK Holdings, expanding and diversifying the portfolio, particularly in healthcare and life sciences, and issuing 6.3 million shares while assuming $33 million of 9% SWK 2027 Notes.

• Net assets decreased to $438.2 million as of March 31, 2026, with net asset value per share at $12.13, down from $13.42 at year-end 2025.

• Announced key leadership changes, including the retirement of the CFO and appointment of a new CFO effective June 30, 2026, and CEO resuming CIO role.

• Maintained a disciplined, credit-first underwriting approach, resulting in a cumulative net loss rate of 0.56% since inception.

• Achieved 32 consecutive quarterly distributions, reflecting stable dividends and operational consistency.

Financial highlights

• Total investment income for Q1 2026 was $29.5 million, down from $35.4 million in Q1 2025.

• Net investment income was $10.6 million ($0.29 per share), compared to $15.6 million ($0.42 per share) in Q1 2025.

• Net asset value per share declined to $12.13 from $13.42 at year-end 2025, with a further post-quarter-end adjustment to $11.93 reflecting SWK transaction costs.

• Portfolio fair value was $886.3 million as of March 31, 2026, down from $927.4 million in Q4 2025.

• Dollar-weighted annualized yield on debt investments was 14.2% for Q1 2026, down from 15.4% in Q1 2025.

Outlook and guidance

• SWK acquisition expected to be accretive to EPS and NII starting Q2 and fully accretive by Q3 2026, expanding dividend coverage.

• Management expects positive contributions from the integrated SWK portfolio, improved diversification, and continued portfolio growth leveraging low leverage and expanded origination channels.

• $372.3 million in available liquidity as of March 31, 2026, including $2.3 million in cash and $370 million in undrawn credit facility.

• Board approved a $15 million share repurchase program in May 2026, reflecting confidence in share value.

• Earnings headwinds anticipated from non-accruals (Marley Spoon, Blueshift, Mingle Healthcare), with a $0.06 per share impact in Q2.